Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
As reported on a Form 8-K filed with the Securities and Exchange Commission on
November 17, 2020, Idera Pharmaceuticals, Inc. (the "Company") previously
announced that R. Clayton Fletcher retired from his role as the Company's Senior
Vice President of Business Development and Strategic Planning, effective
December 31, 2020.
On December 29, 2020 (the "Effective Date"), Company entered into a consulting
services agreement (the "Consulting Agreement") with Mr. Fletcher. The
Consulting Agreement terminates one year following the Effective Date and
provides for aggregate payments to Mr. Fletcher of up to $180,000, to be paid in
equal monthly installments over the term of the Consulting Agreement. The
Consulting Agreement also includes confidentiality and non-solicitation
restrictions.
The foregoing description of the Consulting Agreement is qualified in its
entirety by reference to the Consulting Agreement filed as Exhibit 10.1 to this
Current Report on Form 8-K and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
10.1 Consulting Agreement, dated December 29, 2020, between the Company
and R. Clayton Fletcher.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses